Israeli pharma company Compugen has dosed the first patient in the phase 1 clinical trial which is evaluating the company’s cancer immunotherapy antibody COM701 in patients with advanced solid tumors. COM701 has been designed to target the PVRIG gene, which according to the Israeli pharma company is a novel immune checkpoint target it had identified […]
Continue reading …
South Korean biotech company SillaJen and Hong Kong-based Lee’s Pharmaceutical have enrolled the first patient in China for a phase 3 trial called PHOCUS which will evaluate the oncolytic immunotherapy Pexa-Vec for the treatment of advanced liver cancer. The PHOCUS trial will aim to have 600 patients on board across the world who did not […]
Continue reading …
Novartis has secured approval from the European Commission (EC) for its skin cancer drug combo Tafinlar (dabrafenib) and Mekinist (trametinib) as an adjuvant therapy for stage III patients with BRAF V600 mutation-positive melanoma after complete surgical resection. The latest approval marks the third for the Tafinlar-Mekinist combination in Europe for various tumor types identified with […]
Continue reading …
The European Commission (EC) has approved an expanded indication for Amgen blood cancer drug BLINCYTO (blinatumomab) as monotherapy for the treatment of certain form of acute lymphoblastic leukemia (ALL) in pediatric patients aged one year or older. The pediatric approval of BLINCYTO is for the treatment of patients with Philadelphia chromosome-negative (Ph-) CD19 positive B-cell […]
Continue reading …
Janssen Pharmaceutical has bagged approval from the US Food and Drug Administration (FDA) for its combo of IMBRUVICA (ibrutinib) and rituximab for the treatment of Waldenström’s macroglobulinemia (WM), a rare blood cancer. The FDA approval secured by the Johnson & Johnson subsidiary expands IMBRUVICA’s current label in Waldenström’s macroglobulinemia as a monotherapy to include its […]
Continue reading …
Cantex Pharmaceuticals, a Florida-based biotech company, has secured the fast track designation for its acute myeloid leukemia drug CX-01 from the US Food and Drug Administration (FDA). The FDA fast track designation for CX-01 is for the treatment of patients, aged over 60, who are being subjected to induction therapy for newly diagnosed acute myeloid […]
Continue reading …Aravive Biologics ovarian cancer drug AVB-S6-500 gets FDA fast track designation
August 20, 2018 No Comment
Aravive Biologics has secured fast track designation from the US Food and Drug Administration (FDA) for its ovarian cancer drug AVB-S6-500 for the treatment of platinum-resistant recurrent ovarian cancer. A high-affinity, soluble Fc-fusion protein, AVB-S6-500 has been designed to prevent the activation of the GAS6-AXL signaling pathway. The drug functions by intercepting the binding of […]
Continue reading …
Tolero Pharmaceuticals said that its cyclin-dependent kinase 9 (CDK9) inhibitor alvocidib will be combined with AbbVie leukemia drug venetoclax to evaluate their potential in their treatment of relapsed/refractory acute myeloid leukemia (AML). In this regard, the two companies have entered into a clinical research collaboration while retaining full commercial rights for their respective drugs. According […]
Continue reading …
Lenvima FDA appoval : Eisai and Merck announced that the US Food and Drug Administration (FDA) has approved their kinase inhibitor Lenvima (lenvatinib) capsules for first-line treatment of hepatocellular carcinoma (HCC), a common type of primary liver cancer adults. Lenvima FDA approval, which is for HCC that is unresectable, was driven by results of the […]
Continue reading …Array BioPharma Braftovi triple combo for metastatic colorectal cancer secures FDA breakthrough therapy designation
August 8, 2018 No Comment
Array BioPharma secured breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for encorafenib (BRAFTOVI), in combination with binimetinib (MEKTOVI) and cetuximab for the treatment of patients with a specific form of metastatic colorectal cancer (mCRC). The breakthrough therapy designation is for metastatic colorectal cancer patients who are positive to BRAFV600E mutation as […]
Continue reading …
Business News Today
- Marchex acquires enterprise text analytics company Sonar Technologies
- Matapal gas project : Maersk Drilling bags contract for Maersk Discoverer
- HemaCare to be acquired by Charles River Laboratories for $380m
- Myntra launches luxury fashion store Pernia’s POP-UP SHOP
- Equinox Gold to acquire Canadian gold producer Leagold Mining
- Intel acquires Israeli AI processing company Habana Labs for $2bn
- Amarin bags Vascepa FDA approval for reducing cardiovascular risk
- WPX Energy to acquire Delaware Basin operator Felix Energy for $2.5bn
- Ant Financial, Vanguard create JV for investment advisory services in China
- IFF to acquire DuPont’s Nutrition & Biosciences in $26.2bn deal
